-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a series of research papers from 2013 to 2021, researchers at Weill Cornell Medical College showed that in a phase II clinical trial, when patients with high-risk triple-negative breast cancer (TNBC) receive a When treated with drugs that reduce copper levels in the body, it prolongs the time for cancer to recur and spread or metastasize
"One of the typical characteristics of TNBC is that it is a highly aggressive and difficult-to-treat disease with a high rate of metastatic recurrence and few treatment options
Many biological processes that take place in cells require metal atoms
In order to reduce the content of copper, in early clinical trials and recent animal studies, researchers used a drug called tetrathiomolybdate (TM), which is used to treat a type of copper storage called Wilson disease Disorder and developed
A closer look at the cancer cells treated with TM revealed that these cells altered their metabolism, making it more difficult for them to produce energy
"This paper is based on the research that started in the clinic and we brought it back to the laboratory," said the second author of the article Linda Vahdat, Ph.
Dr.
Dr.
Laboratory research will be an important part of the upcoming trials because the goal is to find the right treatment for the right patient at the right time
Journal Reference :
Ying L.
